The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

详细信息    查看全文

• 作者：Lotta Ljung ; Johan Askling ; Solbritt Rantap??-Dahlqvist…
• 刊名：Arthritis Research & Therapy
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：16
• 期：3
• 全文大小：389 KB
• 参考文献：1. Avina-Zubieta, JA, Thomas, J, Sadatsafavi, M, Lehman, AJ, Lacaille, D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71: pp. 1524-1529 CrossRef
  2. Peters, MJ, van Halm, VP, Voskuyl, AE, Smulders, YM, Boers, M, Lems, WF, Visser, M, Stehouwer, CD, Dekker, JM, Nijpels, G, Heine, R, Dijkmans, BA, Nurmohamed, MT (2009) Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 61: pp. 1571-1579 CrossRef
  3. Solomon, DH, Karlson, EW, Rimm, EB, Cannuscio, CC, Mandl, LA, Manson, JE, Stampfer, MJ, Curhan, GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107: pp. 1303-1307 CrossRef
  4. Turesson, C, Jarenros, A, Jacobsson, L (2004) Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63: pp. 952-955 CrossRef
  5. Holmqvist, ME, Wedrén, S, Jacobsson, LT, Klareskog, L, Nyberg, F, Rantap??-Dahlqvist, S, Alfredsson, L, Askling, J (2010) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 268: pp. 578-585 CrossRef
  6. S?dergren, A, Stegmayr, B, Lundberg, V, ?hman, ML, W?llberg-Jonsson, S (2007) Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 66: pp. 263-266 CrossRef
  7. del Rincón, ID, Williams, K, Stern, MP, Freeman, GL, Escalante, A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44: pp. 2737-2745 CrossRef
  8. Gonzalez, A, Maradit Kremers, H, Crowson, CS, Ballman, KV, Roger, VL, Jacobsen, SJ, O’Fallon, WM, Gabriel, SE (2008) Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 67: pp. 64-69 CrossRef
  9. Innala, L, M?ller, B, Ljung, L, Magnusson, S, Smedby, T, S?dergren, A, ?hman, ML, Rantap??-Dahlqvist, S, W?llberg-Jonsson, S (2011) Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 13: pp. R131 CrossRef
  10. Symmons, DP, Gabriel, SE (2011) Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 7: pp. 399-408 CrossRef
  11. Peters, MJ, Symmons, DP, McCarey, D, Dijkmans, BA, Nicola, P, Kvien, TK, McInnes, IB, Haentzschel, H, Gonzalez-Gay, MA, Provan, S, Semb, A, Sidiropoulos, P, Kitas, G, Smulders, YM, Soubrier, M, Szekanecz, Z, Sattar, N, Nurmohamed, MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69: pp. 325-331 CrossRef
  12. Carmona, L, Descalzo, Má, Perez-Pampin, E, Ruiz-Montesinos, D, Erra, A, Cobo, T, Gómez-Reino, JJ (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66: pp. 880-885 CrossRef
  13. Dixon, WG, Watson, KD, Lunt, M, Hyrich, KL, Silman, AJ, Symmons, DPM (2007) Reduction in the incidence of myocard
• 刊物主题：Rheumatology; Orthopedics;
• 出版者：BioMed Central
• ISSN：1478-6354

文摘

Introduction The elevated risk of ischaemic heart disease in patients with rheumatoid arthritis (RA) has been linked to inflammation and disease severity. Treatment with tumour necrosis factor inhibitors (TNFis) is often effective in reducing disease activity and could possibly modify cardiovascular risk. Our objective in the study was to evaluate the risk of acute coronary syndrome (ACS) in patients with RA treated with TNFis compared with the risk among biologic-na?ve RA patients and the general population. Methods By linkage of the Swedish National Patient Register and the Swedish Biologics Register, we identified a cohort of patients who were started on their first biologic, a TNFi, between 2001 and 2010 (N--,704), and a cohort comprising matched biologic-na?ve RA patient referents at a 3:1 ratio. Furthermore, a matched comparator cohort (5:1 ratio) was extracted from the Swedish population register. The incidence rates of a first ACS event were calculated and compared between cohorts using Cox proportional hazards regression in three different risk windows: ‘ever-exposed- ‘actively on TNFi-and ‘short-term exposure-(active treatment maximized to 2?years). The models were adjusted for disease duration, joint surgery, comorbidity and socioeconomic factors, and, in a sensitivity analysis including a subpopulation started on therapy beginning 1 January 2006 or later, for dispensed drugs. Results Based on 221 events in 7,704 patients (comprising 32,621 person-years) treated with TNFi biologics, the hazard ratio ((HR); ever-exposed) for ACS among the TNFi-exposed RA patients compared with biologic-na?ve RA patients was 0.8 (95% confidence interval (CI)--.7 to 0.95). In comparison with the general population referents, statistical analysis using fully adjusted models resulted in a HR of 2.0 (95% CI--.8 to 2.3) for biologic-na?ve RA patients and a HR of 1.6 (95% CI--.4 to 1.9) for the TNFi-exposed group. Similar risk estimates were obtained using the other two risk windows. A sensitivity analysis in which we compared the TNFi-exposed patients included from 1 January 2006 onward with biologic-na?ve patients resulted in a HR (ever-exposed) of 0.7 (95% CI--.5 to 1.0). Conclusions RA patients treated with TNFi had a lower risk of ACS compared with biologic-na?ve RA patients. Compared with the general population, the risk among patients with RA was elevated, although the difference was less pronounced among the TNFi-exposed patients. This finding could be attributable to the TNFi as such, or it could correspond to a lower degree of inflammation in the TNFi-treated group.